Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials

Background: This study aimed to explore the effects of sodium-glucose co-transporter 2 (SGLT2) on hemoglobin levels in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. Methods: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the China National Knowledge Infrastructure database, Wanfang Digital Periodicals Database (WFDP) and the Chinese Biological and Medical database (CBM) were searched for randomized trials of SGLT2 inhibitors in patients with T2DM and chronic kidney disease up to July 25, 2020. A total of four studies that included 19,259 patients were identified. Results: Compared to control patients, SGLT2 inhibitors were shown to increase hemoglobin levels in patients with T2DM and chronic kidney disease (standard mean difference = 0.70, 95% CI, 0.59-0.82, p < 0.0001). Conclusion: SGLT2 inhibitors may bring additional benefits to patients with T2DM and chronic kidney disease.

Automated summary

This study found that SGLT2 inhibitors can significantly increase hemoglobin levels in patients with T2DM and chronic kidney disease, potentially bringing additional benefits to these patients.